Free Trial

Synlogic (SYBX) Competitors

Synlogic logo
$1.20 0.00 (-0.33%)
Closing price 07/3/2025 01:00 PM Eastern
Extended Trading
$1.20 0.00 (-0.08%)
As of 07/3/2025 04:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SYBX vs. RENB, VTGN, CNTB, OTLK, IZTC, IRD, PMVP, NRXP, GNTA, and SNTI

Should you be buying Synlogic stock or one of its competitors? The main competitors of Synlogic include Renovaro (RENB), VistaGen Therapeutics (VTGN), Connect Biopharma (CNTB), Oncobiologics (OTLK), Invizyne Technologies (IZTC), Opus Genetics (IRD), PMV Pharmaceuticals (PMVP), NRx Pharmaceuticals (NRXP), Genenta Science (GNTA), and Senti Biosciences (SNTI). These companies are all part of the "pharmaceutical products" industry.

Synlogic vs. Its Competitors

Synlogic (NASDAQ:SYBX) and Renovaro (NASDAQ:RENB) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation and institutional ownership.

In the previous week, Renovaro had 3 more articles in the media than Synlogic. MarketBeat recorded 4 mentions for Renovaro and 1 mentions for Synlogic. Renovaro's average media sentiment score of 0.42 beat Synlogic's score of 0.00 indicating that Renovaro is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Synlogic
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Renovaro
0 Very Positive mention(s)
3 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Synlogic has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500. Comparatively, Renovaro has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500.

Synlogic's return on equity of 10.91% beat Renovaro's return on equity.

Company Net Margins Return on Equity Return on Assets
SynlogicN/A 10.91% 7.47%
Renovaro N/A -60.38%-47.04%

63.4% of Synlogic shares are owned by institutional investors. Comparatively, 71.4% of Renovaro shares are owned by institutional investors. 3.0% of Synlogic shares are owned by company insiders. Comparatively, 21.7% of Renovaro shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Synlogic has higher revenue and earnings than Renovaro. Synlogic is trading at a lower price-to-earnings ratio than Renovaro, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Synlogic$10K1,399.32-$23.36M-$2.51-0.48
RenovaroN/AN/A-$88.43M-$0.77-0.36

Summary

Renovaro beats Synlogic on 6 of the 11 factors compared between the two stocks.

Get Synlogic News Delivered to You Automatically

Sign up to receive the latest news and ratings for SYBX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SYBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SYBX vs. The Competition

MetricSynlogicMED IndustryMedical SectorNASDAQ Exchange
Market Cap$13.99M$2.88B$5.49B$9.02B
Dividend YieldN/A2.43%5.38%4.10%
P/E Ratio-0.4821.5627.4720.28
Price / Sales1,399.32244.81408.86121.46
Price / CashN/A41.9536.6357.47
Price / Book1.107.518.095.68
Net Income-$23.36M-$55.05M$3.17B$248.96M
7 Day Performance-3.55%4.61%2.81%3.30%
1 Month Performance-2.76%4.89%3.67%5.20%
1 Year Performance-18.08%5.84%35.41%21.37%

Synlogic Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SYBX
Synlogic
0.5396 of 5 stars
$1.20
-0.3%
N/A-18.1%$13.99M$10K-0.4880Gap Up
RENB
Renovaro
1.1951 of 5 stars
$0.37
+7.9%
N/A-82.4%$58.76MN/A-0.4820Gap Up
High Trading Volume
VTGN
VistaGen Therapeutics
1.4127 of 5 stars
$1.96
-2.0%
N/A-38.8%$58.31M$490K-1.1840
CNTB
Connect Biopharma
3.3528 of 5 stars
$0.98
-5.3%
$7.00
+617.9%
-12.7%$57.23M$26.03M0.00110News Coverage
OTLK
Oncobiologics
1.6972 of 5 stars
$1.68
-1.5%
$9.60
+471.4%
-74.4%$57.23MN/A-1.8520
IZTC
Invizyne Technologies
N/A$9.15
-25.9%
N/AN/A$57.21MN/A0.0029News Coverage
IRD
Opus Genetics
1.6552 of 5 stars
$0.91
-4.6%
$7.33
+709.2%
N/A$56.68M$10.99M-0.4314
PMVP
PMV Pharmaceuticals
2.5491 of 5 stars
$1.07
-1.8%
$5.50
+414.0%
-22.4%$56.63MN/A-0.9150News Coverage
NRXP
NRx Pharmaceuticals
2.0913 of 5 stars
$3.10
-4.9%
$28.50
+819.4%
+28.3%$56.36MN/A-1.542
GNTA
Genenta Science
1.9129 of 5 stars
$3.06
flat
$25.00
+717.0%
+25.2%$55.97MN/A0.007
SNTI
Senti Biosciences
2.7591 of 5 stars
$1.99
-6.6%
$8.50
+327.1%
-30.3%$55.55M$2.56M-0.184

Related Companies and Tools


This page (NASDAQ:SYBX) was last updated on 7/4/2025 by MarketBeat.com Staff
From Our Partners